Healthcare News

ORION OYJ        LEHDISTÖTIEDOTE        10.4.2026 KLO 9.00         Orion julkaisee osavuosikatsauksen 1–3/2026 ja järjestää verkkolähetyksen 23.4.2026 Orion julkaisee osavuosikatsauksen 1–3/2026...

ORION CORPORATION PRESS RELEASE 10 APRIL 2026 at 9.00 EEST         Orion publishes Interim Report for January–March 2026 and holds a webcast on 23 April 2026        Orion will publish Interim Report...

Allschwil, Switzerland – April 10, 2026Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting...

Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 10 april 2026 – 7:00u CEST Fagron organiseert Gewone en Buitengewone Algemene Vergadering op 11 mei 2026 Fagron NV nodigt haar...

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2026 – 7 AM CEST Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026 Fagron NV invites its...

MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug...

Not for distribution to U.S. news wire services or dissemination in the United States. MARKHAM, Ontario, April 09, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:...

EMPAVELIMD (pegcétacoplan) est le premier traitement autorisé dans le traitement des patients adultes et pédiatriques de 12 ans et plus atteints de glomérulopathie à dépôts de C3 (GC3) ou de...

EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced...

RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first...